45 results about "Metered-dose inhaler" patented technology

The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation comprising: (i) a suspension of particles comprising 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554); and (ii) a diluent which is 1,1,1,2-tetrafluoroethane (HFA-134a), wherein the liquid pharmaceutical composition is substantially free of surfactant. The invention also relates to a pressurised metered dose inhaler comprising the liquid pharmaceutical composition.

This disclosure relates to an improved inhalable formulation comprising nicotine, or a pharmaceutically acceptable derivative or salt thereof, a propellant, a C1 to C6 alcohol and a glycol. The disclosure further relates to a metered dose inhaler containing the inhalable nicotine formulation and a method of treating a nicotine addiction with the formulation.

This disclosure relates to an inhalable formulation comprising melatonin and, optionally, a cannabinoid. Furthermore, this disclosure relates to a metered dose inhaler containing the inhalable formulation and methods and uses of the inhalable formulation.

Systems and methods for isolating and / or desiccating a portion of a drug delivery tract of a drug delivery apparatus to reduce water vapor content therein are provided. For example, there is provided a metered dose inhaler for delivering aerosolized medicament or other matter to a user. The aerosolized medicament or other matter may be discharged from a discharge passageway within the inhaler into an inhalation passageway for inhalation by a user, and the inhaler may comprise a seal member operative to selectively isolate the discharge passageway from the inhalation passageway and external environment during inactivity. The inhaler may further comprise a desiccant material arranged to withdraw moisture from the isolated discharge passageway. In other instances, desiccant material may be arranged to withdraw moisture from the discharge passageway of the inhaler without isolating the discharge passage during inactivity.

A medication delivery system having a holding chamber capable of delivering dosages of medicament from a metered dose inhaler. The holding chamber includes an actuator detector, flow detector and display. In another embodiment, a medication delivery system includes a holding chamber having an input and an output end, a metered dose inhaler operably coupled to the input end of the holding chamber, and a metered dose inhaler identifier associated with the holding chamber and operable to identify the metered dose inhaler coupled to the holding chamber.

The present disclosure provides a metered dose inhaler (MDI) comprising an API formulation suitable for administration to a patient in need thereof by inhalation, as well as methods and uses of the MDI.

The invention generally refers to a stainless steel can for use in a metered dose inhaler device, containing an aerosol formulation, comprising glycopyrronium bromide and formoterol, or a salt or a solvate thereof, optionally in combination with one or more additional active ingredient, endowed with a high stability.

Metered dose inhaler device including an actuator housing (10) with a substantially hollow first portion (15) including a nozzle block, and a substantially hollow second portion (25) defining a mouthpiece and located adjacent the substantially hollow first portion. A spray orifice (45) is formed in the nozzle block (30). The spray orifice (45) defines a jet length (46) along an orifice axis. The spray orifice defines an orifice exit (49) with an orifice exit diameter (47). The jet length is at least 0.8 millimeters ("mm"). The device includes a composition including a propellant that includes 1,1-difluoroethane ("HFA-152a") or trans-1, 1,1,3-tetrafluoropropene ("HFO-1234ze(E) "), the composition located in a canister (40) disposed in the substantially hollow first portion (15). Once the composition is ejected from the orifice exit (49), the composition defines a spray pattern. The spray pattern matches that of a similar device using a propellant including 1,1,1,2,3,3,3-heptafluoropropane ("HFA-227") and a jet length less than or equal to 0.8 mm.

A metered dose inhaler equipped with a metering valve and having an aerosol canister containing a pharmaceutical composition comprising propellant, ethanol, citric acid, and tiotropium or a pharmaceutically acceptable salt or solvate thereof dissolved in the composition, wherein the aerosol canister has an internal surface that is a non-metal material that is in contact with the pharmaceutical composition.

To provide a pharmaceutical aerosol formulation for use in a pressurized metered dose inhaler (abbreviated as pMDI or MDI), particularly an improved pharmaceutical aerosol formulation for aerosol administration.SOLUTION: The present invention provides a pharmaceutical aerosol suspension formulation for MDI administration, comprising: (a) an atomization β2-stimulant, (b) micronized corticosteroid, (c) a quasi-therapeutic amount of a moisture scavenging excipient, and (d) an HFA propellant. The (a), (b) and (c) and their respective relevant amounts are selected such that they associate to form fluorocarbon having substantially the same density as that of the HFA (hydrofluoroalkane) propellant.SELECTED DRAWING: None

A pharmaceutical aerosol formulation containing pre-micronized epinephrine, a co-solvent ethanol, a surfactant polysorbate 80, and a propellant trans-1, 3, 3, 3-tetrafluoropropene (HFO-1234ze (E)) for use in a pressurized metered dose inhaler is described. The formulations provide efficient delivery of pre-micronized epinephrine particles into the respiratory tract of a patient, and have the advantages of high therapeutic efficacy, improved safety, and low global warming potential (GWP) affecting the environment.

The invention provides a quantitative aerosol inhalation system, which comprises a mouthpiece, a tee joint, a filter, an atomization device, an electromagnetic valve and a one-way valve, and is characterized in that the system is arranged in the tee joint, when a user exhales from the mouthpiece, the one-way valve is opened, airflow flows out of the filter through the one-way valve, when the user inhales, the one-way valve is closed, and the user can only inhale gas flowing in from the atomization device; and the control module is used for receiving the gas pressure value detected by the pressure detection element and controlling the action of the electromagnetic valve according to the gas pressure value. By means of the quantitative aerosol inhalation system, it can be ensured that aerosol administration is conducted on each patient under the optimal inhalation flow, once the inhalation flow is lower than the optimal flow range, administration is stopped immediately, and the accuracy of aerosol administration is greatly improved; meanwhile, the unique one-way valve design is adopted, and cross infection is eradicated; the dosing dosage can be automatically calculated, so that different dosing dosages can be generated by using a single concentration, and the gallipot does not need to be frequently replaced.

1. A pharmaceutical composition deliverable from a metered dose inhaler, the pharmaceutical composition comprising: a propellant of pharmaceutical grade 1,1-Difluoroethane (HFC-152a); a plurality of active agent particles; and a plurality of phospholipid particles comprising perforated microstructures; wherein the active agent particles comprise an active agent selected from a long-acting muscarinic antagonist (LAMA), a long-acting P2-agonist (LABA), a short-acting beta-agonist (SABA), an inhaled corticosteroid (ICS), and a non-corticosteroid anti-inflammatory agent. A metered dose inhaler comprising a canister with an outlet valve including an actuator for dispensing a metered amount of said pharmaceutical composition, wherein the canister contains the pharmaceutical composition. Said composition for use in the treatment of a pulmonary disease or disorder.

A metered dose inhaler valve (26) has a reservoir portion (37) for assembly with a canister (14) for receiving a pressurised formulation of medicament and propellant, a metering valve body (96) defining a metering chamber, and a metering valve stem (24) having an outlet (56) and being axially moveable within the body. The stem moves between a first position in which the chamber is in fluid communication with the canister, and a second position in which the chamber is in fluid communication with the valve stem outlet. A metering valve seal is defined by the valve body and includes an opening through which the stem passes to form a dynamic seal between the stem and at least one of the outside atmosphere and the pressurized canister, where the opening is adapted to be stretched wider by the stem passing through it than it would be absent the valve stem.

The application provides a quantitative injection device, and relates to the technical field of medical injection devices. The quantitative injection device comprises a shell, a dose sleeve, an indicating piece, a rotating assembly, a push rod assembly and a threaded sleeve. The dose sleeve is sleeved on the shell, the rear end of the dose sleeve is provided with a first ratchet, and the dose sleeve is in threaded transmission with the shell. The indicating piece is installed on the shell, and is used for indicating the dose of a medicament. The rotating assembly is installed on the dose sleeve, the rotating assembly is provided with a second ratchet which is engaged with the first ratchet, and the front end of the rotating assembly is provided with a third ratchet. The push rod assembly is installed on the rotating assembly, the push rod assembly is provided with a fourth ratchet which is engaged with the third ratchet, and the rotating assembly can drive the push rod assembly to rotate. The push rod assembly can move in the front-rear direction relative to the threaded sleeve. The embodiment of the application can solve the problem that the injection dose cannot be steplessly adjusted.

A respiratory delivery care system is characterized by comprising: a mechanical flow indicator movable in response to a user's inhalation and / or exhalation, and an electronic indicator operable in response to an electronic signal transmitted in response to the movement of the flow indicator. The flow indicator is an inspiratory valve, an expiratory valve, or an axially movable actuator. The delivery device includes a retaining chamber wound with a coil and at least one magnet disposed at the center of the coil, the at least one magnet being reciprocating to sense current and store the current in a supercapacitor connected to the circuitry and the electronic indicator. A respiratory delivery device is characterized by comprising: a flow indicator configured to transmit a first input signal, a metered-dose inhaler in communication with the retaining chamber, a lever for actuating the inhaler and having a sensor to transmit a second input signal, and a processor for receiving these signals to generate an output signal.

The present disclosure provides a method of treating asthma in a subject at risk of asthma exacerbation, and a method of as-needed treatment or prevention of bronchoconstriction in a subject, and / or prevention of exacerbation in a subject with asthma, comprising administering as needed to the subject a composition comprising therapeutically effective amounts of albuterol and budesonide, wherein the composition is administered via a metered dose inhaler, wherein the method reduces risk of severe asthma exacerbation by at least about 15% as compared to administration of a composition comprising a same dose of albuterol alone, as measured by time-to-first severe asthma exacerbation. Also provided is a pharmaceutical composition comprising: albuterol and budesonide in the form of particles; a suspension medium comprising a hydrofluoroolefins (HFO) propellant and / or a hydrofluorocarbon propellant (HFC), and a plurality of respirable suspending particles, wherein the particles of albuterol and budesonide associate with the plurality of respirable suspending particles.

The present invention generally relates to an aerosol formulation comprising formoterol, beclomethasone dipropionate and glycopyrronium bromide, the formulation being contained in a coated canister, which formulation is particularly useful for use in pressurized metered dose inhalers for the treatment of respiratory diseases.

The present invention provides a stable pharmaceutical composition to be used with pressurized metered dose inhalers comprising a beta 2 agonist, a corticosteroid, a muscarinic antagonist, HFO propellant, a co-solvent, an organic acid(s) and optionally water. The invention further provides a specific container and a valve system comprising internally coated canister and a valve for storing the composition. The invention also provides a pharmaceutical composition comprising a beta 2 agonist, a corticosteroid, a muscarinic antagonist for the treatment or prophylaxis of asthma, chronic obstructive pulmonary disease (COPD), rhinitis or as adjunct therapy for cystic fibrosis, non-cystic fibrosis bronchiectasis, lung infections or pulmonary fibrosis.

A medication delivery system having a holding chamber capable of delivering dosages of medicament from a metered dose inhaler. The holding chamber includes a first housing component having a user interface with an outlet opening and a second housing component having an inlet opening spaced apart from the outlet opening of the first housing component. The first housing component is pivotally connected to the second housing component about a pivot axis.

An adherence-monitoring and tracking device captures usage of a metered dose inhaler (MDI). The device includes an enclosure for enclosing a metered dose inhaler (MDI), and an electro-mechanical system forming a part of enclosure to sense and log the operation of the MDI. The electro-mechanical system includes at-least one transducer to capture one or more parameters pertaining to an operation of the MDI by the user. A microcontroller processes the captured parameters, and an output-unit renders data pertaining to operation of the MDI.

The present invention relates to pharmaceuticals for inhalation, containing aurothioglucose, and to an inhaler, preferably a powder inhaler, dosing inhaler or atomizer containing such pharmaceuticals. The invention provides these pharmaceuticals for use in the prevention and therapy of pulmonary diseases, in particular infectious and inflammatory-infectious pulmonary diseases. 20 26 20 53 78 07 J ul 2 02 6 2 0 2 6 2 0 2 6 2 0 5 3 7 8 0 7 J u l

The present invention relates to a pressurized metered dose inhaler (pMDI) comprising: a container; a pharmaceutical formation under pressure in the container, said pharmaceutical formulation comprising: (i) about from about 75% by weight to about 87% by weight HFO-1234ze(E); (ii) from about 13% by weight to about 25% by weight of ethanol; and (iii) ipratropium bromide in solution in said ethanol and / or said HFO-1234ze(E); a normally closed valve on the container; and an actuator fluidly connected to the valve and having an orifice diameter of less than 0.5 mm, said valve being actuatable to an open position to release said pharmaceutical formulation to pass through said orifice and produce an aerosol spray containing ipratropium bromide in solution.

The present subject matter discloses an enhancer (100) for delivery of aerosol from a pressurized Metered Dose Inhaler (pMDI, 10) to a user. The enhancer comprises a holding chamber (110), a connector (120) and a one way valve (130). The holding chamber (110) is having a first end (112) configured to receive aerosol from the pMDI (10) and a second end (114) configured to form a mouthpiece (114) for engagement with the user's mouth. The connector (120) is having an adapter end (122) configured to be connected with the pMDI (10) and a pivot end (124) configured to pivotally mount the first end (112) of the holding chamber (110). Further, the connector (120) is configured to swivel the holding chamber (110) around the pivot end (124).

A metered dose inhaler includes ring body open at both ends, the ring body adapted to house a pressurized canister of medicine, an actuator ring including two or more external spring housings containing springs seated and aligned with spring seats formed on a cap attached to the distal end of the ring body the actuator ring fitting over the ring body in concentric fashion partially housing the ring body, the actuator ring having an actuator form fixed to an inside surface thereof to actuate a canister stem installed on the pressurized canister by urging the actuator ring against spring tension over the ring body toward the cap displacing a canister stem to break seal and dispense a dose of medicine.

An asthma diagnosis and management system including a valved holding chamber defining an interior cavity, a backpiece having an opening configured to receive a pressurized metered dose inhaler and a user interface. A microphone is coupled to the valved holding chamber and is in communication with an interior of the valved holding chamber and is configured to capture a sound of a user's lungs.

The invention generally refers to a stainless steel can for use in a metered dose inhaler device, containing an aerosol formulation, comprising glycopyrronium bromide and formoterol, or a salt or a solvate thereof, optionally in combination with one or more additional active ingredient, endowed with a high stability.